Liver Disease Biotech Galmed Files For A $35 Million IPO

– Galmed Pharmaceuticals Ltd., a clinical-stage biotech developing therapies for liver diseases and gallstones, filed on Thursday with the SEC to raise up to $35 million in an initial public offering, More...